C81.00
Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
Clinical Classification Guidelines
Medical Intelligence & Overview
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare form of Hodgkin lymphoma, a type of cancer that originates in the lymphatic system. Unlike the more common variants of Hodgkin lymphoma, NLPHL tends to grow more slowly and often has a different pattern of cell involvement. This condition may develop at any age but is most commonly diagnosed in young and middle-aged adults. It typically presents in lymph nodes but can sometimes be found in other tissues.
Causes & Symptoms
Clinical Causes: The exact cause of NLPHL is unknown. It involves genetic mutations that lead to abnormal growth of lymphocytes. Exposure to certain environmental factors or previous immune system issues might influence risk, though these links are not well-established. Family history of lymphatic cancers may slightly increase risk.
Key Symptoms: Painless swelling of lymph nodes, usually in the neck, armpits, or groin. Persistent fatigue or feeling tired all the time. Unexplained weight loss over a short period. Fever that comes and goes without an obvious infection. Night sweats causing excessive sweating during sleep. Itching all over the body without an apparent cause. Sometimes, symptoms depend on where the lymphoma has spread or grown.
Diagnostic & Treatment
Diagnosis Path: Detecting NLPHL involves a combination of tests and examinations: - Physical examination of lymph nodes to check for swelling. - Blood tests to assess overall health and look for signs of lymphoma. - Imaging studies such as CT scans or PET scans to locate enlarged lymph nodes or other affected areas. - Lymph node biopsy, which is the definitive test, involves removing a small tissue sample for microscopic examination to identify characteristic cells and confirm the diagnosis. - Immunohistochemistry tests help distinguish NLPHL from other types of lymphoma or lymphatic conditions.
Treatment Protocols: Treatment strategies for NLPHL are tailored to the individual’s condition, stage of the disease, and overall health: - **Radiation therapy** is often effective for localized disease. - **Chemotherapy** may be recommended when the disease involves multiple lymph nodes or other sites. - **Immunotherapy** approaches target specific molecules on cancer cells to help the immune system fight the lymphoma. - In some cases, a combination of treatments may be used. - Routine follow-up is necessary to monitor response to treatment and detect any recurrence. While NLPHL generally has a favorable prognosis, ongoing medical supervision is essential to manage the condition effectively.
Clinical Advice & FAQs
Billing Guidance
Is C81.00 a billable ICD-10 code?
Yes, C81.00 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.00?
Clinical documentation must specify the nature of Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site and any associated comorbidities for accurate reporting.
Cite this Clinical Reference